Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Inovio Pharmaceuticals ( (INO) ) has shared an announcement.
On July 2, 2025, INOVIO Pharmaceuticals entered into an underwriting agreement with Piper Sandler & Co. for a public offering of 14,285,715 shares of common stock and accompanying Series A and B warrants. The company expects net proceeds of approximately $22.5 million from the offering, which is anticipated to close around July 7, 2025, subject to customary conditions. This move is expected to bolster INOVIO’s financial position, potentially impacting its market presence and stakeholder interests.
The most recent analyst rating on (INO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Inovio Pharmaceuticals stock, see the INO Stock Forecast page.
Spark’s Take on INO Stock
According to Spark, TipRanks’ AI Analyst, INO is a Neutral.
Inovio Pharmaceuticals faces significant financial and technical challenges, reflected in its low financial performance and valuation scores. While there is progress in regulatory submissions and cost management, ongoing financial difficulties and bearish technical indicators heavily impact the overall score.
To see Spark’s full report on INO stock, click here.
More about Inovio Pharmaceuticals
INOVIO Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases.
Average Trading Volume: 1,038,797
Technical Sentiment Signal: Strong Sell
Current Market Cap: $48.78M
Learn more about INO stock on TipRanks’ Stock Analysis page.